[go: up one dir, main page]

CY1108224T1 - Καινοτομες κρυσταλλικες μορφες ενος αναστολεα του παραγοντα χα - Google Patents

Καινοτομες κρυσταλλικες μορφες ενος αναστολεα του παραγοντα χα

Info

Publication number
CY1108224T1
CY1108224T1 CY20081100790T CY081100790T CY1108224T1 CY 1108224 T1 CY1108224 T1 CY 1108224T1 CY 20081100790 T CY20081100790 T CY 20081100790T CY 081100790 T CY081100790 T CY 081100790T CY 1108224 T1 CY1108224 T1 CY 1108224T1
Authority
CY
Cyprus
Prior art keywords
innovative
crystal forms
suspension factor
factor
suspension
Prior art date
Application number
CY20081100790T
Other languages
English (en)
Inventor
Rick G Woodward
David S Teager
Original Assignee
Aventis Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc. filed Critical Aventis Pharmaceuticals Inc.
Publication of CY1108224T1 publication Critical patent/CY1108224T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Καινοτόμοι κρύσταλλοι ενός αναστολέα του Παράγοντα Xa του χημικού τύπου (I), διαδικασίες για την παρασκευή του, συνθέσεις που τον περιέχουν και η θεραπευτική του χρήση.
CY20081100790T 2000-10-05 2008-07-29 Καινοτομες κρυσταλλικες μορφες ενος αναστολεα του παραγοντα χα CY1108224T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23831600P 2000-10-05 2000-10-05
GBGB0108903.6A GB0108903D0 (en) 2000-10-05 2001-04-10 Novel crystalline forms of a factor Xa inhibitor
EP01979459A EP1326838B1 (en) 2000-10-05 2001-10-04 Novel crystalline forms of a factor xa inhibitor

Publications (1)

Publication Number Publication Date
CY1108224T1 true CY1108224T1 (el) 2014-02-12

Family

ID=22897372

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100790T CY1108224T1 (el) 2000-10-05 2008-07-29 Καινοτομες κρυσταλλικες μορφες ενος αναστολεα του παραγοντα χα

Country Status (14)

Country Link
US (1) US7034160B2 (el)
EP (1) EP1326838B1 (el)
JP (1) JP4177663B2 (el)
AT (1) ATE396177T1 (el)
AU (2) AU2002211425B2 (el)
CA (1) CA2424565C (el)
CY (1) CY1108224T1 (el)
DK (1) DK1326838T3 (el)
ES (1) ES2304396T3 (el)
GB (1) GB0108903D0 (el)
IL (1) IL155189A (el)
MX (1) MXPA03002067A (el)
PT (1) PT1326838E (el)
WO (1) WO2002028836A1 (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6964784B2 (en) * 2002-03-07 2005-11-15 Optigenex, Inc. Method of preparation and composition of a water soluble extract of the bioactive component of the plant species uncaria for enhancing immune, anti-inflammatory, anti-tumor and dna repair processes of warm blooded animals
TWI551289B (zh) * 2011-03-29 2016-10-01 賽諾菲公司 具有改良之安定性之奧米沙班調配物
JP5993933B2 (ja) * 2011-03-29 2016-09-14 サノフイ 安定性を改善したオタミキサバン製剤
HRP20150613T1 (hr) * 2011-03-29 2015-07-17 Sanofi Sol benzojeve kiseline otamiksabana
TWI662964B (zh) 2012-06-04 2019-06-21 美商製藥有限責任公司 布魯頓氏酪胺酸激酶抑制劑之結晶形式
WO2016022942A1 (en) 2014-08-07 2016-02-11 Pharmacyclics Llc Novel formulations of a bruton's tyrosine kinase inhibitor
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
MA41827A (fr) * 2015-03-27 2018-01-30 Pharmacyclics Llc Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080767A (en) * 1996-01-02 2000-06-27 Aventis Pharmaceuticals Products Inc. Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
SI0906094T1 (en) * 1996-01-02 2003-12-31 Aventis Pharmaceuticals Inc. Substituted n- (aminoiminomethyl or aminomethyl)phenyl)propyl amides

Also Published As

Publication number Publication date
CA2424565A1 (en) 2002-04-11
EP1326838A1 (en) 2003-07-16
GB0108903D0 (en) 2001-05-30
AU1142502A (en) 2002-04-15
JP4177663B2 (ja) 2008-11-05
PT1326838E (pt) 2008-07-08
AU2002211425B2 (en) 2006-03-02
JP2004521082A (ja) 2004-07-15
ES2304396T3 (es) 2008-10-16
DK1326838T3 (da) 2008-09-22
ATE396177T1 (de) 2008-06-15
WO2002028836A9 (en) 2003-11-20
EP1326838B1 (en) 2008-05-21
US20030225144A1 (en) 2003-12-04
IL155189A (en) 2011-11-30
US7034160B2 (en) 2006-04-25
CA2424565C (en) 2011-04-26
MXPA03002067A (es) 2003-06-24
WO2002028836A1 (en) 2002-04-11

Similar Documents

Publication Publication Date Title
CY1108224T1 (el) Καινοτομες κρυσταλλικες μορφες ενος αναστολεα του παραγοντα χα
DE60236102D1 (en) 1h-indolderivate als hochselektive cyclooxygenase-2-inhibitoren
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
TNSN07235A1 (en) Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride
EE200300459A (et) Uued spirotritsüklilised derivaadid ja nende kasutamine fosfodiesteraas-7 inhibiitoritena
CY1117051T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν κρυσταλλικη μορφη (i) της υδροχλωριουχου λερκανιδιπινης
TR200401962T4 (tr) Heteroaromatik karboksamid türevleri ve bunların IKK-2 enziminin inhibitörleri olarak kullanımı
GEP20074098B (en) Lactam-containing compounds and derivatives thereof as factor xa inhibitors
WO2003006425A3 (en) Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
YU5503A (sh) Nesteroidni supresori zapaljenja
IL152916A0 (en) Heteroaryl-phenyl heterobicyclic factor xa inhibitors
NO20044731L (no) Kinolin- og isokinolinderivater fremgangsmate for fremstilling derav og anvendelse derav som betennelseshemmere
NO20074275L (no) 2- (4-okso-4H-kinazolin-3-yl) acetamider og deres anvendelse som Vasopressin-V3-antagonister
NO20005265L (no) Substituerte benzamider, deres fremstilling og anvendelse som inhibitorer av cystin-proteaser
NO20024528L (no) Proteaseinhibitor, farmasoytisk sammensetning og anvendelse av forbindelsen
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
ATE380174T1 (de) Arginin-mimetika als faktor xa-inhibitoren
ATE328888T1 (de) Radicicol und monocillin und ihre analogen und ihre anwendungen
SE0103710D0 (sv) Compounds
MXPA03010766A (es) Nuevos compuestos y composiciones como inhibicores de las catepsinas.
DE60216948D1 (en) 4'-methansulfonylbiphenylderivate als hochselektive cyclooxygenase-2-inhibitoren
ATE394414T1 (de) Hemmstoffe des gerinnungsfaktors xa, ihre herstellung und verwendung
MXPA03002493A (es) Proceso eficiente para preparacion de un inhibidor del factor xa.
DE60212130D1 (en) Carvedilolpolymorph
WO2002010124A3 (en) Salt forms of an hiv protease inhibitor